Long Term Outcome of Easophageal Atresia : Transmics Profiles in Adolescence

University Hospital, Lille300 enrolled

Overview

Oesophageal atresia (OAEA), a malformation of the oesophagus present from birth, is characterized by the interruption of the continuity of the oesophagus, which then ends in a cul-de-sac. (Source: Fimatho) An operation is then required to restore continuity to the esophagus. Although this operation enables the vast majority of children to survive the neonatal period, health problems such as gastro-oesophageal reflux, eating difficulties, respiratory problems and growth problems persist throughout life. The aim of the project is to create a prospective cohort of adolescents aged 13/14, nested in the national AO registry. of adolescents born with esophageal atresia, including a biobank of esophageal mucosa and plasma blood samples. Once the clinical and omic data have been collected, the data will be transferred to the France Cohortes information system for analysis, in order to assess the long-term outcome of this rare disease and establish multi-omic profiles. Once the clinical data have been collected and the omics data (derived from analysis of the biobank's biological samples) have been generated, they will be analyzed by the project partners to assess the long-term outcome of OA and establish multiomic profiles. The raw data will be available on the France Cohorte platform.

Study Type

OBSERVATIONAL

Enrollment

300

Conditions

Esophageal Atresia

Interventions

Eligibility

Sex: ALLMin age: 13 YearsMax age: 14 Years

Medical Language ↔ Plain English

Inclusion Criteria: * For the oesophageal atresia group : * Born with oesophageal atresia (EA) in France or in French overseas departments and territories * Anastomosis performed * Included into the ReNaTo registry * Aged 13 or 14 during the recruitment period * Patient willing to comply with all study procedures and duration * Patient will social security For the blood sub-study : * Upper GI endoscopy performed as part of care between 13 and 14 years of age with esophageal mucosal biopsy sampling * Patient having given written consent to participate in the study For the control arm: * Upper GI endoscopy performed as part of care between 10 and 14 years of age with oesophageal mucosal biopsy sampling * Upper GI endoscopy performed as part of care for chronic or acute digestive signs to rule out organic etiology (peptic esophagitis, gastric esophagitis, eosinophilic esophagitis or ulcer) * Normal endoscopy and histology * No chronic progressive disease Exclusion Criteria: * For the oesophagal atresia arm : * Concurrent participation in an interventional trial and in the 3 months prior to inclusion * Parents refusing to participate in the study For the control arm : * Histologically non-normal esophageal biopsy * Parents refusing to participate in the study * Child with known organic pathology

Locations (33)

CHU de Lille Hôpital Jeanne de Flandre

Lille, Nord, France

RECRUITING

CHU Amiens

Amiens, France

NOT_YET_RECRUITING

CHU Angers

Angers, France

RECRUITING

CHU Besançon

Besançon, France

Outcomes

Primary Outcomes

prevalence of gastroesophageal reflux disease (GERD) in children born with esophageal atresia

GERD = \[pH/impedance-metry demonstrating pathological GERD and/or if lesions of peptic esophagitis are observed at an endoscopy in the year preceding the visit or if the child has a history of complicated GERD leading to anti-reflux surgery\]

Time frame: 13-14 years

Secondary Outcomes

Quality of life, nutritional status and respiratory complications

Quality of life= EA-QoL and PedsQL The quality of life of patients in adolescence will be assessed by means of the following quality of life scales at the age of 13-14 years: PedsQL (13) and EA-QoL (11) by both the patient and a parent. Scale scores will be calculated in accordance with the authors' instructions. * Nutritional status will be assessed by weight and height, and by calculating the weight/height z-score and BMI z-score using the World Health Organisation growth curves as a reference (14). * Frequency of respiratory complications, assessed during clinical examination (hacking cough during infections, chronic cough, asthma, exertional symptoms (cough, dyspnoea), atopy, wheezing and/or stridor/corniness).

Time frame: 13-14 years

Omics and multi omics profiles in plasma

Time frame: 13-14 years

Factors associated with GERD

It will be determined from patient characteristics at birth, 1 year, 6 years and 13-14 years (ante-natal data, vital signs, presence of associated malformations, type of atresia, surgical procedures performed, surgical/digestive/respiratory/neuro-orthopaedic complications, type of diet and schooling).

Time frame: Birth,1 year, 6 years and 13-14 years

Omics and multi omics profiles in esophageal biopsiesfor patient having 1 biopsy

metabolites, proteins and methylation

Time frame: 13-14 years

Omics and multi omics profiles in esophageal biopsies for patient having more than 1 biopsy

metabolites, proteins and methylation

Time frame: 13-14 years